Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

Huons

Status and phase: Not yet enrolling; Phase 1

Conditions: Obesity

Treatments: Drug: HUC2-676-R; Drug: HUC2-676

Study type: Interventional

Funder types: Industry

Identifiers

NCT07337174

HUC2-676

Details and patient eligibility

About

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Enrollment: 40 estimated patients

Sex: All

Ages: 19 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
• Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.

Exclusion criteria

• Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
• For females: Pregnant women (positive urine hCG) or nursing mothers.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

HUC2-676

Experimental group

Treatment:

Drug: HUC2-676

HUC2-676-R

Active Comparator group

Treatment:

Drug: HUC2-676-R